Status:
RECRUITING
Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer
Lead Sponsor:
University Health Network, Toronto
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Lung cancer is the leading cause of death in the world. Overall 5-year survival rate is fewer than 10% and the effectiveness of conventional chemotherapy is limited. The new knowledge shows the correl...
Eligibility Criteria
Inclusion
- Age 18 years or older.
- Patients with confirmed or suspected lung cancer who require EBUS-TBNA as part of their staging investigations of the mediastinum will be considered for the trial.
- Patients with undiagnosed enlarged lymph nodes in the mediastinum suspicious for lung cancer in which a tissue diagnosis is required.
Exclusion
- Patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy.
- Patients where there is a high clinical suspicion of lymphoma.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT01487603
Start Date
October 1 2011
End Date
October 1 2025
Last Update
July 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada